Spesolimab: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Spesolimab. Educational only — not medical advice.
Labeled uses
SPEVIGO is indicated for the treatment of generalized pustular psoriasis (GPP) in adults and pediatric patients 12 years of age and older and weighing at least 40 kg.
Source: FDA labeling via NIH DailyMed (set 41a481ee…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.